The antibody recognizes the typical amyloid deposits in brains of patients suffering from the disease. This antibody has been developed against the carboxy terminal extracellular sequence of the mutated BRI protein.
Suitable for Immunohistochemistry on frozen sections. Suggested positive control: pathological brain sections. (Not recommended in Western blots). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
限制
仅限研究用
浓度
1.0 mg /ml
缓冲液
PBS, pH 7.2, containing 0.09 % sodium azide as preservative.
储存液
Sodium azide
注意事项
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
注意事项
Avoid repeated freezing and thawing.
储存条件
4 °C/-20 °C
储存方法
Store the antibody at 2-8 °C (Lyophilized) or reconstituted in small aliquots at -20 °C.
The mutated BRI protein (ITM2B) was identified in patients with familial British dementia. The unusual 277 residue precursor protein releases a 34-residue amyloidogenic peptide by the action of the protease furin, leading to the deposition of a protein fragment that seems to be involved in the pathogenesis of familial British dementia.Synonyms: BRI, BRI2, ITM2B, Integral membrane protein 2B, Transmembrane protein BRI